BPC-157 and FDA compounding lists: what Category 2 and the 2026 advisory meeting do and do not mean

The question this guide answers

Readers often see a peptide described as "on the FDA list," "Category 2," or "voted through" and ask what that means for its legal status. These phrases refer to a narrow process: which bulk drug substances a licensed pharmacist or physician may use when compounding under section 503A of the Federal Food, Drug, and Cosmetic Act. This guide explains that vocabulary from FDA pages reviewed on 13 October 2026.

Peptide Fieldnotes covers documentation and regulatory status for research procurement. Nothing here is a recommendation to obtain, compound or use any peptide, and nothing here describes dosing, treatment or benefit. A status note is not a safety assessment.

How a bulk substance becomes usable in 503A compounding

FDA explains that a 503A compounder may use a bulk drug substance that complies with an applicable USP or NF monograph, is a component of an FDA-approved drug, or appears on FDA's 503A Bulks List. The bulk substance must also be accompanied by a valid certificate of analysis and be made by an establishment registered with FDA. [2]

Substances nominated for the list but not yet decided are handled under an interim policy. FDA describes Category 1 as nominated substances that may be eligible for the list, were nominated with sufficient supporting information and appear on no other list; FDA does not intend to take action against compounders using them if the policy's conditions are met. Category 2 substances had sufficient information, but FDA identified significant safety risks, so the Category 1 policy does not apply. Category 3 substances lacked sufficient supporting information and may be re-nominated. [2]

Where BPC-157 and other peptides appear on FDA's safety-risk page

FDA's page on bulk substances that may present significant safety risks, current as of 22 April 2026, contains a Category 2 table and a separate table of substances that were nominated but withdrawn. Peptides in the Category 2 table at review included GHRP-2, GHRP-6, ipamorelin acetate and kisspeptin-10. The withdrawn-nomination table included BPC-157, TB-500 (thymosin beta-4 fragment), CJC-1295, KPV, MOTs-C, epitalon, semax, selank, thymosin alpha 1 and others, without dates or reasons for withdrawal. [1]

For BPC-157, the page states that compounded drugs containing it may pose a risk for immunogenicity for certain routes of administration and that FDA identified no, or only limited, safety-related information for the proposed routes. Record such statements verbatim with the page's "content current as of" date; do not paraphrase them into a stronger or weaker claim. [1]

What the July 2026 advisory meeting did

FDA's Pharmacy Compounding Advisory Committee met on 23 and 24 July 2026 to discuss BPC-157, KPV, TB-500 and MOTs-C on the first day, and emideltide (DSIP), semax and epitalon on the second, each in free-base and acetate forms, for possible inclusion on the 503A Bulks List. The meeting page notes that advisory committees make non-binding recommendations to FDA. [3]

FDA's briefing document for that meeting proposes that each listed substance not be included on the list, and states that FDA does not intend to issue a final determination until the advisory committee input has been considered and all reviews are finalized. When we checked the FDA meeting page on 13 October 2026, it listed briefing materials, agenda, roster and presentations but no voting results, minutes or final determination. News reports of a committee vote exist; we do not treat them as an FDA decision. [3] [4]

Write a status record that will stay accurate

Status pages change. Capture the exact page, its "content current as of" date and your access date, and quote the relevant row. A useful note reads: "On 13 October 2026, FDA's safety-risk page listed substance S in the withdrawn-nomination table; the July 2026 briefing document proposed non-inclusion; no final determination was posted." That sentence is checkable and does not overstate.

Keep three distinctions explicit. First, compounding status is separate from approval: FDA states that compounded drugs are not FDA approved. [5] Second, an advisory recommendation is not a final listing. Third, a supplier selling material labeled for research use is a different channel from a licensed pharmacy compounding under section 503A; do not cite a compounding status as evidence about a research supplier's product or documentation.

• Quote the FDA row and table name rather than summarizing it as "approved" or "banned".
• Recheck the meeting page and the safety-risk page before republishing any status note.
• Route any clinical or legal question to an appropriately qualified professional; this record is not advice.